Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-261-3 | CAS number: 7803-55-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Study period:
- 2010-05-18 to 2010-09-04
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Version / remarks:
- , 1992-07-17
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 2009-11-12
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- sodium metavanadate
- IUPAC Name:
- sodium metavanadate
- Reference substance name:
- Sodium metavanadate
- EC Number:
- 237-272-7
- EC Name:
- Sodium metavanadate
- IUPAC Name:
- 237-272-7
- Reference substance name:
- 13718-26-8
- Cas Number:
- 13718-26-8
- IUPAC Name:
- 13718-26-8
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): Sodium metavanadate
- Trivial name: Sodium metavanadate
- Molecular formula: NaVO3
- Molecular weight: 121.93 g/mol
- Physical state: Solid; white powder
- Storage condition of test material: Kept cool and dry in tightly sealed containers
- pH: Approx. 9 (2.5% solution)
-Melting point: 630°C
- Water solubility: 211 g/L
- Relative density: 2.9 [MSDS provided by the producer]
No further information on the test material was stated.
Constituent 1
Constituent 2
Constituent 3
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services Germany GmbH, Stolzenseeweg 32 – 36, 88353 Kißlegg, Germany
- Age at study initiation: 32 days
- Weight at study initiation: 325 - 361 g (excluding positive control group); Positive control group: 312 - 381 g
- Housing: The animals were kept in pairs in MAKROLON cages (MZK 80/25). Granulated textured wood (Granulat A2, J. BRANDENBURG, 49424 Goldenstedt, Germany) was used as bedding material in the cages.
- Diet (ad libitum): Commercial diet, ssniff® Ms-H V2233 (ssniff Spezialdiäten GmbH, 59494 Soest, Germany)
- Water (ad libitum): Tap water
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 20°C ± 3°C (maximum range)
- Relative humidity (%): 55% ± 15% (maximum range)
- Photoperiod (hrs dark / hrs light): 12/12
No further information on the test animals was stated.
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal and epicutaneous
- Vehicle:
- water
- Remarks:
- Aqua ad iniectabilia (Batch nos. 911728 and 002152; Delta Select GmbH, 63303 Dreieich, Germany)
- Concentration / amount:
- Intracutaneous (Induction): 0.01% solution of sodium metavanadate in aqua ad iniectabilia
Topical (induction): 1% solution of sodium metavanadate in aqua ad iniectabilia
Topical (challenge): 0.05% solution of sodium metavanadate in aqua ad iniectabilia
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- water
- Remarks:
- Aqua ad iniectabilia (Batch nos. 911728 and 002152; Delta Select GmbH, 63303 Dreieich, Germany)
- Concentration / amount:
- Intracutaneous (Induction): 0.01% solution of sodium metavanadate in aqua ad iniectabilia
Topical (induction): 1% solution of sodium metavanadate in aqua ad iniectabilia
Topical (challenge): 0.05% solution of sodium metavanadate in aqua ad iniectabilia
- No. of animals per dose:
- Preliminary test: 16 animals
Main test: 10 animals (treatment group) plus 5 animals (vehicle control group)
Positive control group: 20 animals - Details on study design:
- RANGE FINDING TESTS:
The aim of the preliminary study was to determine the appropriate dose level of the test item following intracutaneous and topical administration. The concentration used in the main study following the induction procedure should produce mild to moderate (grade 1 or grade 2) skin reactions following topical application and be adjusted to the highest level that can be well tolerated locally and generally following intracutaneous injection. For the challenge exposure a subirritating concentration was used which produced no evidence of skin irritation in non-sensitised animals.
The shoulder and the flank region of the animals were shaved or shaved and depilated (approx. 5 cm x 5 cm).
(a) intracutaneous: 0.1 mL of the prepared test item was administered intracutaneously (shoulder region).
Three concentrations of the test item were injected intradermally into four animals, respectively. In all, twelve concentrations were tested intracutaneously.
(b) topical: The test area of 12 animals was shaved (6 animals) or shaved and depilated (6 animals). 2 mL of the test preparation was spread over a filter paper (2 cm x 4 cm) and applied to the test area and held in contact by an occlusive dressing.
Two concentrations each were applied to the shaved or shaved and depilated flanks.
The occlusive dressing and the filter paper containing the test item were removed after 24 or 48 hours and the application sites were assessed immediately, 24 and 48 (depilated) or immediately and 24 hours (non-depilated) after removal of the filter paper for erythema and oedema using the grading of MAGNUSSON/KLIGMAN.
Results:
Twelve concentrations of sodium metavanadate were tested by intracutaneous injection: 0.00001, 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.1, 0.5, 1, 5 or 10% solutions in aqua ad iniectabilia.
Concentrations up to 0.005% did not reveal any skin reaction. A concentration of 0.01% revealed a moderate and confluent erythema 24, 48 and 72 hours after administration. A concentration of 0.1% revealed a moderate and confluent erythema 24 hours and an intense erythema and swelling 48 and 72 hours after administration. A concentration of 0.5% revealed an intense erythema and swelling 24, 48 and 72 hours after administration. The animal employed with the concentrations of 1, 5 and 10% died prematurely within 24 hours after administration.
Twelve concentrations of sodium metavanadate were tested by topical application: 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1 0.5, 1, 5, 10, 25 and 50% concentrations in aqua ad iniectabilia.
Non-depilated skin: Concentrations up to 0.05% did not reveal any skin reactions. Concentrations of 0.1 or 0.5% revealed a discrete or patchy erythema, a concentrations of or 5% revealed a moderate and confluent erythema, concentrations of 10% and above revealed an intense erythema and swelling 48 and 72 hours after start of administration, respectively.
Depilated skin: Concentrations up to of 0.05% did not reveal any skin reactions. A concentration of 0.1% revealed a discrete or patchy erythema 24, 48 and 72 hours after start of administration. A concentration of 0.5% revealed a moderate and confluent erythema 24 hours and an intense erythema 48 and 72 hours after start of administration. Concentrations of 1% and above revealed an intense erythema and swelling 24, 48 and 72 hours after start of administration.
It was decided to use a 0.01% solution for the 1st (intracutaneous) induction stage, a concentration of 1% for the 2nd (topical) induction stage and a 0.05% concentration for the challenge.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intradermal injection and topical administration)
- Test groups:
Stage 1:
Day 0
Three pairs of intradermal injections of 0.1 mL were given in the shoulder region which was cleared of hair so that one of each pair lay on each side of midline.
(1) Freund's complete adjuvant (Batch no. 049K8700; SIGMA-ALDRICH Chemie GmbH, 82024 Taufkirchen, Germany)(diluted 1 : 1 with 0.9% NaCl (Batch no. 005632; Delta Select GmbH, 63303 Dreieich, Germany))
(2) the test item (sodium metavanadate) (0.01 % in aqua ad iniectabilia)
(3) the test item in a 1:1 mixture (v/v) FCA/physiological saline
In injection 3, the final concentration of the test item was equal to that in injection 2.
Stage 2
Day 7
7 days after the intracutaneous injection, the shoulder region of the same animals was shaved again and treated topically using the patch-test technique (as described above under "Range finding tests)(exposure time: 48 hours). The patch was removed after 48 hours. No cleaning of the skin was necessary.
- Control group:
The vehicle control animals were treated in the same way as the animals of the test group, but received aqua ad iniectabilia instead of the test item.
Skin observations and scoring: The skin reaction results of the first induction exposure were evaluated at 24 and 48 hours, of the second induction at 48 and 72 hours after start of exposure. The skin reactions were graded following the grading scale of MAGNUSSON/KLIGMAN.
B. CHALLENGE EXPOSURE
- No. of exposures:
- Test groups:
Two weeks (Day 21) after the topical application (corresponds to a monitoring period of 21 days) the flanks of the same animals were shaved and depilated for a further topical application using the patch-test technique (as described above under "Range finding tests). The filter paper containing the test item was applied to the left flank, the filter paper with the vehicle to the right flank of the animal (exposure time: 24 hours). 21 hours after the filter paper had been removed the treated skin was cleaned and fur removed, if necessary.
- Control group:
The left flank was treated with the test item, the right flank with the vehicle i.e. in the same way as the test group.
- Evaluation (hr after challenge): 21 hours after removing the filter paper the challenge area was cleaned and cleared of hair if necessary. Three hours later (at 48 hours from the start of challenge application) the skin reaction was observed and recorded. 24 hours after this observation a second observation (72 hours) was made and recorded. The skin reactions were graded following the grading scale of MAGNUSSON/KLIGMAN.
OTHER OBSERVATIONS:
Mortality: daily during the observation period
Clinical signs: daily during the observation period
Body weight: at start of study and at study termination
Pathology: No necropsy was performed. No animal was found dead in the main study or was sacrificed in extremis.
POSITIVE CONTROL GROUP:
The animals of the positive control group (same origin (strain) as those used in the study) were treated with a 2% (w/v) benzocaine solution intracutaneously in stage 1 , a 5% (w/v) benzocaine solution topically in stage 2 and in stage 3. The positive control data are obtained from the historical background of the laboratory that conducted this study. The study was performed during March 2010.
No further information on the study design was stated. - Challenge controls:
- Vehicle control group: aqua ad iniectabilia
5 males were used for the vehicle control group. - Positive control substance(s):
- yes
- Remarks:
- Benzocaine (dissolved in 40% ethanolic 0.9% NaCl solution)
Study design: in vivo (LLNA)
- Statistics:
- The body weight was analysed statistically using STUDENT's t-test (p ≤ 0.01).
Results and discussion
- Positive control results:
- Animals of this strain treated with benzocaine in 40% ethanolic 0.9% NaCl solution exhibited a sensitising reaction in all animals in form of a moderate and confluent erythema or an intense erythema and swelling.
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 0.05% solution of sodium metavanadate in aqua ad iniectabilia
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No skin irritation was observed.
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 0.05% solution of sodium metavanadate in aqua ad iniectabilia. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No skin irritation was observed..
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 0.05% solution of sodium metavanadate in aqua ad iniectabilia
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No skin irritation was observed.
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.05% solution of sodium metavanadate in aqua ad iniectabilia. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No skin irritation was observed..
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0.05% solution of sodium metavanadate in aqua ad iniectabilia
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- The vehicle control revealed no skin reactions.
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0.05% solution of sodium metavanadate in aqua ad iniectabilia. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: The vehicle control revealed no skin reactions..
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0.05% solution of sodium metavanadate in aqua ad iniectabilia
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- The vehicle control revealed no skin reactions.
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0.05% solution of sodium metavanadate in aqua ad iniectabilia. No with. + reactions: 0.0. Total no. in groups: 5.0. Clinical observations: The vehicle control revealed no skin reactions..
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 5% (w/v) benzocaine solution (benzocaine was dissolved in 40% ethanolic 0.9% NaCl solution)
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- Animals exhibited a sensitising reaction in form of a moderate and confluent erythema or an intense erythema and swelling.
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 1st reading. . Hours after challenge: 24.0. Group: positive control. Dose level: 5% (w/v) benzocaine solution (benzocaine was dissolved in 40% ethanolic 0.9% NaCl solution) . No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: Animals exhibited a sensitising reaction in form of a moderate and confluent erythema or an intense erythema and swelling. .
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 5% (w/v) benzocaine solution (benzocaine was dissolved in 40% ethanolic 0.9% NaCl solution)
- No. with + reactions:
- 20
- Total no. in group:
- 20
- Clinical observations:
- Animals exhibited a sensitising reaction in form of a moderate and confluent erythema or an intense erythema and swelling.
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 2nd reading. . Hours after challenge: 48.0. Group: positive control. Dose level: 5% (w/v) benzocaine solution (benzocaine was dissolved in 40% ethanolic 0.9% NaCl solution) . No with. + reactions: 20.0. Total no. in groups: 20.0. Clinical observations: Animals exhibited a sensitising reaction in form of a moderate and confluent erythema or an intense erythema and swelling. .
Any other information on results incl. tables
A 0.01% solution of sodium metavanadate i naqua ad iniectabilia chosen for the 1st (intracutaneous) induction stage revealed in all 10 animals a moderate and confluent erythema 24 hours and a discrete or patchy erythema 48 hours after administration.
2 mL of a 1% concentration of sodium metavanadate in aqua ad iniectabilia/animal chosen for the 2nd (topical) induction stage revealed in all 10 animals a discrete or patchy erythema 48 and 72 hours after start of exposure.
The challenge with 2 mL of a 0.05% solution of sodium metavanadate in aqua ad iniectabilia/animal revealed no skin irritation in any animal and, thus, the test item had no sensitising properties.
The body weight gain of the animals treated with sodium metavanadate was within the range of the vehicle control during the experiment.
Behaviour remained unchanged.
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the present test conditions, sodium metavanadate revealed no sensitising properties in guinea pigs in a test model according to MAGNUSSON and KLIGMAN.
Therefore, sodium metavanadate must not be classified and labeled according to regulation (EC) No.: 1272/2008 and subsequent regulations.
Also, sodium metavanadate must not be classified and labeled according to 67/548/EC and subsequent regulations.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)